
Benzinga Pro data, Avidity Biosciences (NASDAQ:RNA) reported Q4 sales of $1.85 million. Earnings fell to a loss of $38.54 million, resulting in a 31.65% decrease from last quarter. In Q3, Avidity Biosciences brought in $2.16 million in sales but lost $29.27 million in earnings.